(NYSE: IMA) announced today that it has resumed repurchase of its
common stock on the open market, as part of its stock repurchase
authorization.

"Purchase of our own stock is one of the various investment opportunities to which we give continuing attention," said M. Blake Ingle, IMCERA president and chief operating officer. "Repurchase at this time reaffirms our belief in the long-term prospects of the company, and it will enhance shareholder value."
IMCERA's board of directors reinstated IMCERA's repurchase authorization program last October. It had been suspended last April due to a common stock equity offering that was completed last year. There are currently 14.4 million shares remaining in the repurchase authorization.
A Fortune 300 company with net sales of more than $1.6 billion in fiscal 1991, IMCERA provides human and animal health care products and specialty chemicals through its three international, technology-based businesses -- Mallinckrodt Medical of St. Louis; Mallinckrodt Specialty Chemicals of Chesterfield, Missouri; and Pitman-Moore of Lake Forest, Ill.
-0- 2/20/92
/CONTACT: Dave Prichard of IMCERA, 708-205-2270/
(IMA) CO: IMCERA Group Inc. ST: Illinois IN: CHM SU:

KD -- NY094 -- 1149 02/20/92 17:24 EST

COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.